Manufacturer
PFIZER (PERTH) PTY. LTD.
Contents
Carboplatin
Indication
Advanced ovarian carcinoma, Small cell lung cancer
Instruction
Adult: Previously untreated patients: 400 mg/m2 as single short term IV infusion over 15-60 min. Therapy should not be repeated until 4 wk after the previous course and/or until the neutrophil count is at least 2,000 cells/mm3 and the platelet count is at least 100,000 cells/mm3. Patients previously treated w/ myelosuppresive therapy or patients w/ poor performance status: Reduce initial dosage by 20-25% (300-320 mg/m2).
Drug interaction
Additive myelosuppressive effects w/ other myelosuppressive agents. Increased risk of nephrotoxicity and/or ototoxicity w/ aminoglycosides or diuretics. Excessive immunosuppression w/ risk of lymphoproliferation w/ ciclosporin. Increased risk of exacerbation of convulsions w/ phenytoin, fosphenytoin. Enhanced adverse/toxic effects of live attenuated vaccines. Potentially Fatal: Risk of generalised disease mortal w/ yellow fever vaccine.
Malaysia
